Angela,
You have two options for the trial which is great news. Both vaccines have benefitted patients.The only difference I see is prior clinical trial results for DCvax has been significant and having the crossover arm with disease progression is a positive. I found the prior data from the DCvax trial which I have enclosed below for you. Hope this helps and good luck with your mom!
Northwest Biotherapeutics, Inc, announced longterm follow-up data for the second half of 2008, from its prior phase I and phase I/II clinical trials with DCVax-Brain in patients with glioblastoma multiforme.During the update period from June 15, 2008, through January 1, 2009, none of the 20 patients treated with standard of care plus DCVax-Brain died. So far, 68% of patients treated with DCVax-Brain have lived more than 2 years, 63% have lived more than 2½ years, 53% have lived more than 3 years, 35% have lived more than 4 years, and 25% have lived more than 5 years.In contrast, patients who receive full standard of care (surgery, radiation, and chemotherapy) without DCVax-Brain have a median survival of only 14.6 months, and less than 5% of these patients are typically alive at 5 years.
In addition, only 2 of the 20 patients experienced progression or recurrence of their brain cancer. One of these two patients had been disease-free for nearly 6 years at the time of their progression, and the other patient had been disease-free for more than 4 years. The usual time toprogression in glioblastoma, with full standard-of-care treatment but without DCVax-Brain, is only 6.9 months.